Abstract
Commercial PCB mixtures have been shown to induce liver tumors in female rats and this effect has been attributed to the effects of PCBs on estrogen metabolism. Catechol metabolites of PCBs are potent inhibitors of COMT activity and are likely to contribute significantly to reduced clearance of genotoxic catechol metabolites of estrogen. The effect of PCB metabolites on COMT expression in cultured cells was investigated to explore potential mechanisms by which PCB exposure alters catechol estrogen clearance. We hypothesize that estrogenic PCB metabolites may contribute to reduction of COMT expression via interaction with the estrogen receptor. To test this hypothesis, human MCF-7 cells were exposed to PCB analogues and the expression of COMT determined. Western blot analysis demonstrated that COMT protein levels were statistically significantly reduced by both the phenolic and the catechol compounds, an effect which was abolished by the anti-estrogen, ICI182780. The above suggests that COMT levels may be reduced by estrogenic PCB metabolites, via interactions between PCB metabolites and the ER. It supports the hypothesis that both phenolic and catechol metabolites of PCBs may contribute to PCB-mediated carcinogenesis through reduction of COMT levels and activities and subsequent reduction in clearance of endogenous and xenobiotic catechols.
Keywords: COMT, carcinogenesis, xenobiotic catechols, PCB, estrogen
Current Drug Metabolism
Title: Estrogenic Phenol and Catechol Metabolites of PCBs Modulate Catechol-Omethyltransferase Expression Via the Estrogen Receptor: Potential Contribution to Cancer Risk
Volume: 9 Issue: 4
Author(s): P. W.L. Ho, C. E. Garner, J. W.M. Ho, K. C. Leung, A. C.Y. Chu, K. H.H. Kwok, M. H.W. Kung, L. T. Burka, D. B. Ramsden and S. L. Ho
Affiliation:
Keywords: COMT, carcinogenesis, xenobiotic catechols, PCB, estrogen
Abstract: Commercial PCB mixtures have been shown to induce liver tumors in female rats and this effect has been attributed to the effects of PCBs on estrogen metabolism. Catechol metabolites of PCBs are potent inhibitors of COMT activity and are likely to contribute significantly to reduced clearance of genotoxic catechol metabolites of estrogen. The effect of PCB metabolites on COMT expression in cultured cells was investigated to explore potential mechanisms by which PCB exposure alters catechol estrogen clearance. We hypothesize that estrogenic PCB metabolites may contribute to reduction of COMT expression via interaction with the estrogen receptor. To test this hypothesis, human MCF-7 cells were exposed to PCB analogues and the expression of COMT determined. Western blot analysis demonstrated that COMT protein levels were statistically significantly reduced by both the phenolic and the catechol compounds, an effect which was abolished by the anti-estrogen, ICI182780. The above suggests that COMT levels may be reduced by estrogenic PCB metabolites, via interactions between PCB metabolites and the ER. It supports the hypothesis that both phenolic and catechol metabolites of PCBs may contribute to PCB-mediated carcinogenesis through reduction of COMT levels and activities and subsequent reduction in clearance of endogenous and xenobiotic catechols.
Export Options
About this article
Cite this article as:
Ho W.L. P., Garner E. C., Ho W.M. J., Leung C. K., Chu C.Y. A., Kwok H.H. K., Kung H.W. M., Burka T. L., Ramsden B. D. and Ho L. S., Estrogenic Phenol and Catechol Metabolites of PCBs Modulate Catechol-Omethyltransferase Expression Via the Estrogen Receptor: Potential Contribution to Cancer Risk, Current Drug Metabolism 2008; 9 (4) . https://dx.doi.org/10.2174/138920008784220600
DOI https://dx.doi.org/10.2174/138920008784220600 |
Print ISSN 1389-2002 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5453 |
![](/images/wayfinder.jpg)
- Author Guidelines
- Bentham Author Support Services (BASS)
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Pharmacological Drug Delivery Strategies for Improved Therapeutic Effects: Recent Advances
Current Pharmaceutical Design Cancer Stem Cells: The ‘Achilles Heel’ of Chemo-Resistant Tumors
Recent Patents on Anti-Cancer Drug Discovery Ontogeny of Human Conjugating Enzymes
Drug Metabolism Letters Natural Products as Aromatase Inhibitors
Anti-Cancer Agents in Medicinal Chemistry The Role of Melatonin in the Immuno-Neuro-Psychology of Mental Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Generation of Pharmacophore and Atom Based 3D-QSAR Model of Novel Isoquinolin-1-one and Quinazolin-4-one-type Inhibitors of TNFα
Medicinal Chemistry Radiation-Induced Extracranial Carotid Stenosis
Vascular Disease Prevention (Discontinued) Design, Synthesis and Biological Evaluation of 3-(3,4,5-Trimethoxyphenyl)- 5-(2-(5-arylbenzo[b]thiophen-3-yl)oxazol-5-yl)isoxazole Derivatives as Anticancer Agents
Letters in Organic Chemistry Thiopurine Biotransformation and Pharmacological Effects: Contribution of Oxidative Stress
Current Drug Metabolism Efficacy of Therapy with c-Met/HGF Inhibitors in Solid Tumors: A Systematic Review Based on 24 Clinical Trials
Clinical Cancer Drugs New Cell Therapy Using Bone Marrow-Derived Stem Cells/Endothelial Progenitor Cells to Accelerate Neovascularization in Healing of Experimental Ulcerative Colitis
Current Pharmaceutical Design Review on EGFR Inhibitors: Critical Updates
Mini-Reviews in Medicinal Chemistry Challenges in the Correct Assessment of a Case of Aggressive Thyroid Carcinoma with Synchronous Breast Cancer: A Case Report and Review of the Literature of Essential Role of Radiopharmaceuticals
Current Radiopharmaceuticals Lymphoid-Specific Tyrosine Phosphatase (Lyp): A Potential Drug Target For Treatment of Autoimmune Diseases
Current Drug Targets Economic and Cost-Effectiveness Considerations for Pharmacogenetics Tests: An Integral Part of Translational Research and Innovation Uptake in Personalized Medicine
Current Pharmacogenomics and Personalized Medicine Understanding the Role of Poloxamer 407 based Thermoreversible In Situ Gelling Hydrogel for Delivery of PEGylated Melphalan Conjugate
Current Drug Delivery In Silico Analysis and Molecular Docking Studies of Novel 6,7-dihydropyrano [2,3-d] pyrimidin-5-one Derivatives as Human Epidermal Growth Factor Receptor 2 (HER2) and Epidermal Growth Factor Receptor (EGFR) Inhibitors
Current Cancer Therapy Reviews Targeted Delivery of Short Interfering RNAs - Strategies for In Vivo Delivery
Recent Patents on Anti-Cancer Drug Discovery Vitamin D and Cancer Stem Cells in the Gastrointestinal Tract
Current Medicinal Chemistry The Chemistry and Biology of the Bryostatins: Potential PKC Inhibitors in Clinical Development
Current Medicinal Chemistry